The DOI matches its Crossref record; 291 of the 293 references it cites were found in a registry or an index.
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Open accessAbstract
Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This interest and use of CAM is common in pediatric IBD, despite being limited evidence for the role of diet and other types of CAMs in inducing and maintaining disease remission in IBD (excluding exclusive enteral nutrition in pediatric Crohn’s disease) [22,23,24].”
From Online Acceptance and Commitment Therapy and Nutrition Workshop for Parents of Children with Inflammatory Bowel Disease: Feasibility, Acceptability, and Initial Effectiveness. (2021) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L., Schreiber, S., Colombel, J., Rachmilewitz, D., Wolf, D. C., Olson, A. D., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,164
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A. A., Rachmilewitz, D., Lichtiger, S., D’Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,184
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,748
Colombel, J., Sandborn, W. J., Rutgeerts, P. J., Enns, R. A., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,239
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P. J., Fedorak, R. N., Lukáš, M., MacIntosh, D. G., Panaccione, R., Wolf, D. C., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,711
Pediatric modification of the Montreal classification for inflammatory bowel disease
Levine, A., Griffiths, A. M., Markowitz, J. F., Wilson, D. C., Turner, D., Russell, R. K., Fell, J. M. E., Ruemmele, F. M., Walters, T. D., Sherlock, M. E., et al. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21493 · Cited by 1,518
Dignass, A. U., Assche, G. V., Lindsay, J. O., Lémann, M., Söderholm, J. D., Colombel, J., Danese, S., D’Hoore, A., Gassull, M. À., Gomollón, F., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,508
Levine, A., Koletzko, S., Turner, D., Escher, J. C., Cucchiara, S., de Ridder, L., Kolho, K., Veres, G., Russell, R. K., Pærregaard, A., et al. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000239 · Cited by 1,403
Flagged first, then by citations
2 of the 293 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Griffiths, 2004, Specificitiesofinflammatoryboweldiseaseinchildhood, BestPractResClinGastroenterol, 18, 509
- Seidman, 1991, Elemental diet versus prednisone as initial therapy in Crohn's disease: early and long term results, Gastroenterology, 100, A250
- Seidman, 1993, Semi-elemental (S-E) diet versus prednisone in pediatric Crohn's disease. Gastroenterology 1993, Gastroenterology, 104, A778
Cited by
Sorted by citations
Items 801–900 of 999
Infliximab More Effective in Therapy‐Naïve Than in Therapy‐Refractory Patients
Cozijnsen, M. A., & de Ridder, L. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000884 · Cited by 2
Winter, R. W., & Burakoff, R. B. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1266935 · Cited by 2
Nutritional Management of Inflammatory Bowel Disease
Otley, A. R., Day, A. S., & Zachos, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-14744-9_27 · Cited by 2
Vitebskaya, A. V., Владимировна, П. А., Afonina, E. Y., Kostina, Y. O., Aleksanyan, K. V., Грамматопуло, М. И., Yablokova, E. A., & Shpitonkova, O. V. (2019) · Diabetes Mellitus · doi:10.14341/dm10042 · Cited by 1
Miyoshi, J., Saito, D., Nakamura, M., Miura, M., Mitsui, T., Kudo, T., Murakami, S., Matsuura, M., & Hisamatsu, T. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/7086939 · Cited by 1
“Hindawi Gastroenterology Research and Practice Volume 2020, Article ID 7086939, 11 pages https://doi.org/10.1155/2020/7086939 The guideline on clinical nutrition in IBD by the European Society for Clinical Nutrition and Metabolism (ESPEN) [5] and the consensus guideline for pediatric CD by the European Society of Pedi…”
BackgroundInfluentialContemporary Dietary Therapies in Inflammatory Bowel Disease
Kaenkumchorn, T. K., Musburger, B., & Suskind, D. L. (2021) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-021-00220-z · Cited by 1
Martins, A. L., Fróes, R. D. S. B., & Zago-Gomes, M. D. P. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i4.341 · Cited by 1
Working to Answer the Effectiveness of Nutrition in IBD: Still a Ways to Go
Otley, A. R., Grover, Z., & Moayyedi, P. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002040 · Cited by 1
Screti, C., Atkinson, L., Shaw, R. L., Muhammed, R., & Heath, G. (2024) · Journal of Child Health Care · doi:10.1177/13674935241310893 · Cited by 2
“Exclusive enteral nutrition is also an effective non-pharmacological treatment used to induce remission in young people with IBD (Carroll et al., 2019; Ruemmele et al., 2014).”
Inpatient Nutritional Considerations in Inflammatory Bowel Disease
Chirayath, S. G., Bahirwani, J. T., Pandey, A., Memel, Z. N., Park, S., & Schneider, Y. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-024-00958-0 · Cited by 1
Wong, M. C. Y., Rotondi, G., Avanzini, S., Arrigo, S., & Mattioli, G. (2025) · Pediatric Surgery International · doi:10.1007/s00383-024-05961-0 · Cited by 1
Debnath, P., Acord, M. R., Anton, C. G., Courtier, J. L., El-Ali, A. M., Forbes-Amrhein, M. M., Gee, M. S., Greer, M. C., Guillerman, R. P., Kocaoğlu, M., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11469-5 · Cited by 1
“Children with Crohn ’ s disease (CD) may develop in fl am-mation of the perianal and/or perineal regions in addition to intestinal involvement [1].”
Kastl, A., Gibble, T. H., Tinsley, D., Crandall, W., Komocsar, W. J., Du, Y., Choong, C., Jha, P., & Chan, W. M. M. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00489-8 · Cited by 1
Exclusive Enteral Nutrition as an Effective Treatment in Inflammatory Bowel Disease
Pérez-González, A., & Hajra, I. E. (2025) · Recent Progress in Nutrition · doi:10.21926/rpn.2502010 · Cited by 1
Tailoring therapy to the individuals of Crohn's disease
Gao, X., & Zhang, Q. (2025) · Science Progress · doi:10.1177/00368504251341943 · Cited by 1
“22 As for maintenance therapy, thiopurines are recommended as one option of steroid free remission in children at risk for poor disease outcome, but not alone as induction therapy.”
InfluentialThe Role of Diet in Crohn’s Disease: From Etiology to Evidence-Based Management
Jamal, F., Alatout, M. H., Khan, M. A., Pasha, S. B., & Malik, T. A. (2025) · Cureus · doi:10.7759/cureus.86891 · Cited by 1
“Regular monitoring of growth parameters and pubertal development is recommended, with timely intervention to address nutritional deficits and optimize bone health [221].”
Konys, C. A., Usman, Y., & Runde, J. (2025) · Pediatric Annals · doi:10.3928/19382359-20250612-04 · Cited by 1
Micallef, S., Mintoff, F., Ellul, P., & Sciberras, M. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003050 · Cited by 1
Alzubaidi, W. R., Alsehli, M. A., Alhazmi, Y. M., Alnefaie, F. A., Allehaibi, N. S., Alghamdi, A. A., & Mohaini, M. A. (2025) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_76_25 · Cited by 1
Experience in Managing Children with Crohn’s Disease in a Gastroenterology Department
Sharuda, E. V., Шеина, О. П., Ilyinskaya, O. E., & Estebesova, Y. R. (2025) · USMU Medical Bulletin · doi:10.52420/usmumb.10.3.e00173 · Cited by 1
Kono-S Anastomosis in Pediatric Crohn’s Disease: Experience at a Tertiary Referral Center
Dipasquale, V., Romano, C., Romeo, C., Impellizzeri, P., Montalto, A. S., & Navarra, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207403 · Cited by 1
Inflammatory Bowel Disease in Jordanian Children: A Tertiary Center Experience
Al-Momani, H., Alsmadi, A., Issi, N., AlShurman, M. A., & Altamimi, E. M. (2025) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2025.28.6.393 · Cited by 1
Axi, L., Wang, Y., & Meng, W. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf236 · Cited by 1
Matsuzawa, H., Ito, Z., Uchiyama, K., Motoi, Y., Ohtaki, Y., Iwashita, Y., Suzuki, S., Nakada, T., Koido, S., Kojima, K., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i2.112132 · Cited by 1
Alexanidou, E., Hörning, A., de Laffolie, J., Choudhury, A. R., Däbritz, J., CEDATA-Studiengruppe, A. E. U., der CEDATA-AG*:, M., & Ernährung:, M. D. A. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2699-7377 · Cited by 1
Trends in drug use and prescription patterns for Crohn’s disease patients in China, 2018–2022
Wang, L., Zhou, L., Zhu, Y. H., Zhao, M., & Wu, F. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14230-w · Cited by 1
“Importantly, although complete enteral nutrition is recommended as first-line therapy to induce remission in pediatric Crohn’s patients [55], evidence for primary nutrition in adults is limited and requires further study [56].”
Pulmonary Function in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis
Moriki, D., Drosakis, I., Koumpagioti, D., Mavronasou, A., Kalogiannis, M., Tsouprou, M., Kourti, A., Fessatou, S., Kortianou, E. A., & Douros, K. (2026) · Pediatric Pulmonology · doi:10.1002/ppul.71580 · Cited by 2
Marind, E. C., & McCullough, F. S. W. (2026) · Nutrients · doi:10.3390/nu18071146 · Cited by 1
“For remission induction, exclusive enteral nutrition (EEN) for 6–8 weeks has been widely recommended as a first-line treatment for children according to consensus guidelines conducted by ECCO/ESPGHAN [12].”
An, Y., Gilmore, R., Radford‐Smith, G. L., & Begun, J. (2026) · JGH Open · doi:10.1002/jgh3.70394 · Cited by 1
Wei, Q., Guan, D., Fang, Y., Guo, J., Wu, J., & Xu, X. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102829 · Cited by 1
Deng, X., Huang, Z., Xia, Q., Huang, Z., Wu, Y., Wu, Y., Li, Q., Diao, N., Li, M., Tang, J., et al. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70135 · Cited by 1
Sasson, G., Hosmer, C., & Korzenik, J. R. (2026) · Nutrients · doi:10.3390/nu18142240 · Cited by 1
“…studied dietary intervention in CD, and it is currently first-line therapy for induction of remission in mild-to-moderate active CD in the European Crohn’s Colitis Organization and European Society of Pediatric Gastroenterology, Hepatology and Nutrition consensus guideline recommendations [7,8].”
Dileo, I., Vernero, M., Ribaldone, D. G., Chiarotto, A., Avico, A. J., Bosa, C., Ossola, M., Ponzo, V., Caviglia, G. P., & Bo, S. (2026) · Nutrients · doi:10.3390/nu18152491 · Cited by 1
Duggan, M. P., Katsanos, E. D., & Hamandi, H. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70534 · Cited by 1
Patel, P. V., Moses, J., Ali, S. A., Suskind, D. L., Pasternak, B. A., Kaplan, J. L., Samson, C., Manning, L., & Adler, J. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.08.008 · Cited by 1
Zheng, H. B., Doran, B. A., Kimler, K., Yu, A., Tkachev, V., Niederlová, V., Cribbin, K., Fleming, R., Bratrude, B., Betz, K., et al. (2026) · eLife · doi:10.7554/elife.91792.3 · Cited by 1
Quand et comment utiliser la vidéocapsule endoscopique de l’intestin grêle chez l’enfant ?
Viala, J., Michaud, L., Bellaiche, M. M., & Lachaux, A. (2017) · Archives de Pédiatrie · doi:10.1016/j.arcped.2017.01.003 · Cited by 1
Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
Jung, D., Lee, S., Jeong, I., Oh, S. H., & Kim, K. M. (2017) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2017.20.4.236 · Cited by 1
“Each treatment has its own strengths and weaknesses [4], and numerous studies have been published to compare their effectiveness and present guidelines for treatment [5].”
BackgroundCorbera-Hincapie, M. A., & Beasley, G. L. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00083 · Cited by 1
Chronisch entzündliche Darmerkrankungen
Gerner, P. (2018) · Springer eBooks · doi:10.1007/978-3-662-52783-2_20 · Cited by 1
Probiotics in Paediatric Practice
Biljana, B. (2019) · The Central European Journal of Paediatrics · doi:10.5457/p2005-114.224 · Cited by 1
Martín‐Masot, R., Pérez, M. P. O., Rueda, N. R., Nieto, J. S., Blasco‐Alonso, J., & Navas‐López, V. M. (2019) · Anales de Pediatría · doi:10.1016/j.anpedi.2019.10.005 · Cited by 1
“…de AZA pueda ayudar a mantener la remisión sin necesidad de administrar nuevos fármacos, tal y como reco-miendan las guías de práctica clínica 3,15 , ya que estudios previos describen tasas de remisión mayores dependientes de la dosis de AZA y de 6-MMP Otra de las ventajas potenciales de la…”
Konecka, N., Kikut, J., & Szczuko, M. (2020) · Pomeranian Journal of Life Sciences · doi:10.21164/pomjlifesci.552 · Cited by 1
Yogev, D., Shosberger, A., Nehemia, C., Harel, S., Yerushalmy‐Feler, A., Ledder, O., Orlanski‐Meyer, E., Assa, A., Slae, M., Kori, M., et al. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003133 · Cited by 1
“Practical guidelines for managing PIBD, and quality items for PIBD referral centers guide optimization of the quality of care (4,13,14).”
BackgroundComplexity of paediatric trials restricts effect on clinical practice
Kolho, K. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00173-4 · Cited by 1
Efficacy of Exclusive Enteral Nutrition in Pediatric Crohn’s Disease
Rodrigues, L., Moeda, S., Loreto, H., Azevedo, S., Asseiceira, I., Maltez, C., Fernandes, A., Mourato, A. P., & Lopes, A. I. (2021) · Nutrición clínica y dietética hospitalaria/Nutrición clínica, dietética hospitalaria · doi:10.12873/412rodrigues · Cited by 1
“It involves the use of a whole protein formula given exclusively for six to eight weeks 4-6 .”
Wasilewska, A., Ponanta-Gawron, K., Burtan, B., Sagaran, C. S. C., Duplaga, M., & Kowalska‐Duplaga, K. (2022) · Journal of Medicinal Food · doi:10.1089/jmf.2021.0069 · Cited by 1
“Steroids in seven children and antitumor necrosis factor a treatment in six cases were added to gain remission or due to exacerbation of CD.”
InfluentialRosh, J. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-49215-5_31 · Cited by 1
Samson, C. M., & Escher, J. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-49215-5_29 · Cited by 1
Tumour necrosis factor-alpha antagonists for treatment of paediatric Crohn’s disease
Gana, J. C., Sepúlveda, A., Orlanski‐Meyer, E., del Pino, L. A. V., Bustamante, M. J. D. L. P., & Labbe, M. T. O. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014497 · Cited by 1
Deep Learning for Predicting Pediatric Crohn's Disease Using Histopathological Imaging
Sharma, A. H., Lawlor, B. W., Wang, J. Y., Sharma, Y., Sengupta, S., Fernandes, P., Zulqarnain, F., May, E., Syed, S., & Brown, D. E. (2022) · Systems and Information Engineering Design Symposium · doi:10.1109/sieds55548.2022.9799299 · Cited by 1
Growth Impairment in Pediatric Inflammatory Bowel Disease
Huang, J. G., & Walters, T. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-14744-9_12 · Cited by 1
Constanza Bay, M., Paulina Núñez, F., Quera, R., & Yarur, A. J. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.10.002 · Cited by 1
Wu, R., Jin, Y., Cao, J., Wang, P., Wang, C., Chen, W., Wu, Y., Zheng, X., Jin, Y., & Yang, H. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.931004 · Cited by 1
“Although exclusive enteral nutrition (EEN) is one of the effective treatments for pediatric CD and has been recommended as the first-line treatment (11, 12), the influence of different types of nutritional formulas, especially different protein compositions, on the effectiveness of EEN for treatment of active CD is st…”
BackgroundField, J. S., Shah, N. D., Memel, Z. N., Mahadevan, U., & Beck, K. R. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08345-5 · Cited by 1
“…the dietary antigens exposed to the gut microbiome, may serve as a corticosteroid-free alternative for the treatment of CD. Multiple studies have demonstrated that Exclusive Enteral Nutrition (EEN) is an alternative to steroid therapy in achieving clinical and endoscopic remission in CD [1–4].”
Harvey, A., Mannette, J., Boneh, R. S., MacIntyre, B., Parrott, M. D., Cahill, L. E., Connors, J., Otley, A. R., Haskett, J., Limbergen, J. V., et al. (2024) · Canadian Journal of Dietetic Practice and Research · doi:10.3148/cjdpr-2024-005 · Cited by 1
Lendner, N., Perry, S., Sferra, T. J., Moses, J., & Young, D. D. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12246 · Cited by 1
Recent advances in the diagnosis and management of Behçet’s syndrome uveitis
Kechida, M., Bazewicz, M., Nabi, W., Daadaa, S., Willermain, F., Abroug, N., Makhoul, D., Ksiaa, I., Jelliti, B., Khochtali, S., et al. (2024) · Expert Review of Ophthalmology · doi:10.1080/17469899.2024.2385652 · Cited by 1
“Eventhough azathioprine was not reported to be associated with increased risk of cancer related mortality, patient should be periodically checked for the development of non-melanoma skin cancer and lymphoma [66].”
Mi, L., Wang, K., Yao, J., Ma, J., Chen, Y., Zeng, Q., & Liu, K. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s485079 · Cited by 2
Versteegh, H. P., Huijgen, D., Meeussen, C. J. H. M., Escher, J. C., & Sloots, C. E. J. (2024) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2024.162105 · Cited by 1
Matran, E. R., Diaconu, A.-M., Iordache, A. M., Dijmărescu, I., Coroleucă, A., Păcurar, D., & Becheanu, C. A. (2025) · Pharmaceuticals · doi:10.3390/ph18010084 · Cited by 1
“European Crohn’s and Colitis Organization (ECCO)/ESPGHAN guidelines recommend subcutaneous administration: 2.4 mg/kg initially, 1.2 mg/kg at week 2, and 0.6 mg/kg every other week for maintenance [17].”
InfluentialInfliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus
Ben‐Horin, S., Ungar, B., Eliakim, R., & Langevitz, P. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw034 · Cited by 1
Variation in inflammatory bowel disease care among saudi pediatric gastroenterologists
Sarkhy, A. A. A. (2017) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.199115 · Cited by 1
“[13,14] The current ECCO/ESPGHAN consensus guidelines recommend treatment individualization based on benefit‐risk stratification.[9]”
BackgroundMethodInfluentialCrohn's disease for the general physician: presentation and investigations
Barlow, J., & Hawthorne, A. (2017) · British Journal of Hospital Medicine · doi:10.12968/hmed.2017.78.2.72 · Cited by 1
Kozioł-Kozakowska, A., Wasilewska, A., Piórecka, B., & Fyderek, K. (2017) · Pediatria Polska · doi:10.1016/j.pepo.2017.03.018 · Cited by 1
Pediatric Crohn's Disease and Surgery: Another Tool for the Treatment of a Complex Disease
Trindade, E. (2016) · GE Portuguese Journal of Gastroenterology · doi:10.1016/j.jpge.2016.05.002 · Cited by 1
Epidemiology of Crohn’s Disease in Japan
Uchiyama, K., Umesawa, M., Haruyama, Y., Sairenchi, T., & Kobashi, G. (2018) · Current topics in environmental health and preventive medicine · doi:10.1007/978-981-13-1096-6_9 · Cited by 1
Arvonen, M., & Stoll, M. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-79026-8_17 · Cited by 1
Oshlyanska, O. A., Березенко, В. С., Nadtochiy, T. G., Doroshenko, A. O., Artzymovich, A. G., & Крат, В. В. (2019) · PERINATOLOGIYA I PEDIATRIYA · doi:10.15574/pp.2019.77.85 · Cited by 1
Modráčková, N., Bunešová, V., Vlková, E., Musilová, Š., Mrvikova, I., Bronský, J., Čopová, I., Hradský, O., & Nevoral, J. (2019) · Journal of Medicinal Food · doi:10.1089/jmf.2019.0021 · Cited by 1
“1,7,12 Furthermore, it can be used to treat relapse, 13 and is closely associated with changes to the patient microbiota and the suppression of intestinal dysbiosis.”
Crohn's disease in a girl with VACTERL association: Can mitochondrial dysfunction coexist?
Peña-Vélez, R., Almanza-Miranda, E., & Zaragoza-Arévalo, G. R. (2019) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2018.10.003 · Cited by 1
Safety of anti-TNF biologics in paediatric inflammatory bowel disease
Ruemmele, F. M. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30292-4 · Cited by 1
To the question of the differential diagnosis of fever of unknown origin in children: a special case
Oshlyanska, O. A., Muzyka, N. M., Archakova, T. М., Nadtochiy, T. G., & Doroshenko, A. O. (2019) · Ukrainian journal of Perinatology and Pediatrics · doi:10.15574/pp.2019.79.49 · Cited by 1
Harmonizing Nutritional Therapies for Pediatric Inflammatory Bowel Disease
Picoraro, J. A., Akabas, S., & LeLeiko, N. S. (2019) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002602 · Cited by 1
“With a favorable side effect profile, EEN is a first-line therapy for pediatric patients with CD under guidelines endorsed by the European Society of Pediatric Gastroenterology, Hepatology and Nutrition and the European Crohn’s and Colitis Organization (11).”
BackgroundMartin, N. G., Roberts, A. J., Evans, H., Bishop, J., & Day, A. S. (2020) · JGH Open · doi:10.1002/jgh3.12310 · Cited by 1
Pérez, A. I. P., Muncunill, G. P., Sánchez, P. D., Feo‐Ortega, S., & de Carpi, J. M. (2020) · Anales de Pediatría · doi:10.1016/j.anpedi.2020.03.017 · Cited by 1
Ha, C., Kim, E. S., Kwon, Y., Choe, Y. H., Kim, M. J., & Lee, S. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s279446 · Cited by 1
Pérez, A. I. P., Muncunill, G. P., Sánchez, P. D., Feo‐Ortega, S., & de Carpi, J. M. (2021) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2020.03.017 · Cited by 1
Unique Challenges in the Diagnosis and Management of the Pediatric IBD Patient
Morganstern, J. A., & Schosheim, A. (2021) · Clinical gastroenterology · doi:10.1007/978-3-030-81780-0_9 · Cited by 1
A whole-food exclusion diet as monotherapy for Crohn's disease
Sasson, A. N. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00335-6 · Cited by 1
Clinical Indices for Pediatric Inflammatory Bowel Disease Research
Turner, D., & Ledder, O. (2017) · Springer eBooks · doi:10.1007/978-3-319-49215-5_46 · Cited by 1
Perianal disease as the first manifestation in paediatric Crohn's disease
Solís, A. M. S., Antuña, L. F., Cuadra, Y. R., & Castellarnau, E. (2020) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2019.11.011 · Cited by 1
Choi, Y. M., Kim, J. M., Moon, J. S., Ko, J. S., & Yang, H. R. (2023) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003731 · Cited by 1
“MTX administration has been recommended as either primary maintenance or after TP therapy failure in pediatric CD patients (2).”
BackgroundBashir, N. S. (2019) · TSpace (University of Toronto) · Cited by 1
Healey, G. R., Tsai, K., Lisko, D. J., Cook, L. E., Vallance, B. A., & Jacobson, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.02.429403 · Cited by 1
Diet‐Based Microbiome Modulation: You are What You Eat
Li, J., Qu, Z., Liu, F., Hao, J., Pan, Y., Guo, S., & Ho, C. L. (2022) · Wiley eBooks · doi:10.1002/9783527825462.ch1 · Cited by 1
The Microbiome, diet and health
OECD (2017) · OECD science, technology and industry policy papers · doi:10.1787/d496f56d-en · Cited by 1
The Prevention and Treatment of Neuropathic and Visceral Pain
Baerg, K., & Mesaroli, G. (2024) · doi:10.1002/9781119645641.ch8 · Cited by 1
Diagnosing and Managing Inflammatory Bowel Disease in Young Children
Alkureishi, L. A., Hageman, J. R., & Biank, V. (2024) · Pediatric Annals · doi:10.3928/19382359-20241022-01 · Cited by 1
Zheng, H. B., Doran, B. A., Kimler, K., Yu, A., Tkachev, V., Niederlová, V., Cribbin, K., Fleming, R., Bratrude, B., Betz, K., et al. (2025) · eLife · doi:10.7554/elife.91792.2 · Cited by 1
Nutritional Management of Inflammatory Bowel Disease
Otley, A. R., Day, A. S., & Zachos, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5061-0_28
Parzęcka, M., Szaflarska‐Popławska, A., Nowicka, M., & Kowalczyk, A. (2015) · Pediatria Polska · doi:10.1016/j.pepo.2015.01.007
The ‘Ideal' Anti-TNF Patient: Indications for Anti-TNF Therapy in Crohn's Disease
Tran‐Minh, M., Baudry, C., & Allez, M. (2015) · Frontiers of gastrointestinal research · doi:10.1159/000381597
Maladie de Crohn chez l’enfant : place de la prise en charge nutritionnelle
Hubert, G., Willot, S., & Caldari, D. (2015) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2015.09.007
Stephens, M., & Mavis, A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5061-0_26
Morbus Crohn und Colitis ulcerosa bei Kindern und Jugendlichen
Keller, K. (2015) · Springer eBooks · doi:10.1007/978-3-642-54671-6_154-1
Indications et techniques de la vidéocapsule endoscopique de l’intestin grêle chez l’enfant
Lachaux, A. (2016) · Acta Endoscopica · doi:10.1007/s10190-016-0529-2
“Pour analyser au mieux l’intestin grêle, il a été récemment recommandé d’utiliser la VCE chez l’enfant [37].”
Jarzębicka, D., Sieczkowska, J., Oracz, G., & Kierkuś, J. (2015) · Postępy Nauk Medycznych · doi:10.5604/08606196.1190918
“The indications for the therapy with anti-TNF are active, severe inflammation of the intestines and/or perianal lesions with the ineffectiveness of the drugs with less potency (1, 3-8).”
BackgroundQuand débuter une nutrition entérale?
Dubern, B. (2015) · Archives de Pédiatrie · doi:10.1016/s0929-693x(15)30031-2
Probiotics and Crohn’s Disease
Kroeker, K. I., & Lu, C. (2016) · InTech eBooks · doi:10.5772/64870
“In the recent ECCO/ESPGHAN guidelines, exclusive enteral nutrition is recommended as first-line therapy to induce remission in children with active luminal CD [7].”
Background
Metadata
- Authors
- Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., Buderus, S., Martín-de-Carpi, J., De Ridder, L., Fagerberg, U. L., Hugot, J. P., Kierkus, J., Kolacek, S., Koletzko, S., Lionetti, P., Miele, E., Navas López, V. M., Paerregaard, A., Russell, R. K., Serban, D. E., Shaoul, R., Van Rheenen, P., Veereman, G., Weiss, B., Wilson, D., Dignass, A., Eliakim, A., Winter, H., & Turner, D.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Semmelweis University (HU)
- Helsinki University Hospital (FI)
- University of Toronto (CA)
- Tel Aviv University (IL)
- Erasmus MC (NL)
- Unit of Paediatric Gastroenterology, Hospital S. João, A Hernani Monteiro, 4202-451, Porto, Portugal
- Istituto Giannina Gaslini (IT)
- University Children's Hospital Zurich (CH)
- Department of Pediatrics, University Hospital Motol, Uvalu 84, 150 06 Prague, Czech Republic
- St. Marien-Hospital Bonn (DE)
- Department of Paediatric Gastroenterolgoy, Hepatology and Nutrition, Hospital Sant Joan de Déu, Paseo Sant Joan de Déu 2, 08950 Barcelona, Spain
- Department of Paediatric Gastroenterology, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, Netherlands
- Karolinska Institutet (SE)
- Sorbonne Paris Cité (FR)
- Department of Gastroenterology, Hepatology and Feeding Disorders, Instytut Pomnik Centrum Zdrowia Dziecka, Ul. Dzieci Polskich 20, 04-730 Warsaw, Poland
- Department of Paediatric Gastroenterology, Children's Hospital, University of Zagreb Medical School, Klaićeva 16, 10000 Zagreb, Croatia
- Department of Paediatric Gastroenterology, Dr. von Hauner Children's Hospital, Lindwurmstr. 4, 80337 Munich, Germany
- Meyer Children's Hospital (IT)
- University of Naples Federico II (IT)
- Paediatric Gastroenterology and Nutrition Unit, Hospital Materno Infantil, Avda. Arroyo de los Ángeles s/n, 29009 Málaga, Spain
- Department of Paediatrics 460, Hvidovre University Hospital, Kettegård Allé 30, 2650 Hvidovre, Denmark
- Department of Paediatric Gastroenterology, Yorkhill Hospital, Dalnair Street, Glasgow G3 8SJ, United Kingdom
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Rambam Health Care Campus (IL)
- Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen, Netherlands
- Queen Fabiola Children's University Hospital (BE)
- Sheba Medical Center (IL)
- Royal Hospital for Sick Children (GB)
- Agaplesion Markus Hospital (DE)
- Massachusetts General Hospital (US)
- Hebrew University of Jerusalem (IL)
- Corresponding author
- Ruemmele, F.M.
- ORCID
- Venue
- Journal of Crohn s and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10-01
- Volume
- 8
- Issue
- 10
- Pages
- 1179-1207
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2135936774
- Cited by
- 1,083
- References
- 293
- Citations by year
- 2026: 61 · 2025: 60 · 2024: 71 · 2023: 97 · 2022: 83 · 2021: 123 · 2020: 117 · 2019: 136 · 2018: 92 · 2017: 122 · 2016: 61 · 2015: 52 · 2014: 5
- FWCI
- 52.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Crohn s and Colitis (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Surgery › Anorectal Disease Treatments and Outcomes
- Keywords
- pediatric Crohn's disease, medical management
- MeSH terms
- Adalimumab, Infliximab, Adolescent, Adrenal Cortex Hormones, Algorithms, Aminosalicylic Acids, Anti-Inflammatory Agents, Non-Steroidal, Anti-Bacterial Agents, Antibodies, Monoclonal, Azathioprine, Child, Crohn Disease, Enteral Nutrition, Humans, Immunosuppressive Agents, Methotrexate, Remission Induction, Thalidomide, Tumor Necrosis Factor-alpha, Mercaptopurine, Maintenance Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
